The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery
Open accessAbstract
Virtual screening (VS) has emerged in drug discovery as a powerful computational tool to screen large libraries of small molecules for new hits with desired properties that can then be tested experimentally. Similar to other computational approaches, VS intention is not to replace in vitro or in vivo assays, but to speed up the discovery process, to reduce the number of candidates to be tested experimentally and to rationalize their choice. Moreover, VS has become very popular in pharmaceutical companies and academic organizations due to its time-, cost-, resources-, and labor-saving. When the biological target is not known or when its 3D structure or the binding mode of ligands are not available, quantitative structure-activity relationship (QSAR) analysis can be used in VS due to their high speed of screening and good hit rate. This approach is known as QSAR-based VS. In this method, compounds with known biological property are collected from databases and the literature. Then, after data curation, chemical descriptors are calculated on different levels of representation of molecular structure, ranging from 1D to nD, where n = 0-7, and then correlated with the biological property using machine learning methods. Once developed and validated, QSAR models are applied to predict the biological property of untested compounds. Although the experimental validation of computational hits does not represent part of the QSAR methodology, this should be performed as a final step of this approach. In this mini-review, we summarize and critically analyze the recent trends of QSAR-based VS approaches in drug discovery, and demonstrate successful applications in identifying perspective compounds with desired properties. Moreover, we provide some recommendations about best practices for the QSAR-based virtual screening along with the future perspectives of this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Colley, D. G., Bustinduy, A. L., Secor, W. E., & King, C. H. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61949-2 · Cited by 2,444
p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure
Hansch, C., & Fujita, T. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a035 · Cited by 2,313 · cited 1×
“Quantitative structure–activity relationship (QSAR) analysis is a ligand-based drug design method developed more than 50 years ago by Hansch and Fujita (1964).”
MethodQSAR Modeling: Where have you been? Where are you going to?
Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., Dearden, J., Gramatica, P., Martin, Y. C., Todeschini, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4004285 · Cited by 2,164
Self-citationBest Practices for QSAR Model Development, Validation, and Exploitation
Tropsha, A. (2010) · Molecular Informatics · doi:10.1002/minf.201000061 · Cited by 2,024
Salmina, E., Haider, N., & Tetko, I. (2015) · Molecules · doi:10.3390/molecules21010001 · Cited by 1,041
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895 · cited 1×
“The 5-hydroxytryptamine 1A (5-HT 1A ) serotonin receptor has been an attractive target for treating mood and anxiety disorders such as schizophrenia (Nichols and Nichols, 2008; Lacivita et al., 2012).”
BackgroundFourches, D., Muratov, E., & Tropsha, A. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100176x · Cited by 832
Self-citationDeep learning for computational chemistry
Goh, G. B., Hodas, N. O., & Vishnu, A. (2017) · Journal of Computational Chemistry · doi:10.1002/jcc.24764 · Cited by 809
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 649
Antimalarial Drug Resistance: A Threat to Malaria Elimination
Menard, D., & Dondorp, A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025619 · Cited by 499
Machine learning methods in chemoinformatics
Mitchell, J. B. O. (2014) · WIREs Computational Molecular Science · doi:10.1002/wcms.1183 · Cited by 469
Apparent activity in high-throughput screening: origins of compound-dependent assay interference
Thorne, N., Auld, D. S., & Inglese, J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.020 · Cited by 430
Kuntz, A. N., Davioud-Charvet, E., Sayed, A. A., Califf, L. L., Dessolin, J., Arnér, E. S. J., & Williams, D. L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040206 · Cited by 365
Current status and prospects of HIV treatment
Cihlar, T., & Fordyce, M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.03.004 · Cited by 337
Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation
Fourches, D., Muratov, E., & Tropsha, A. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00129 · Cited by 294
Self-citationAre the Chemical Structures in Your QSAR Correct?
Young, D., Martin, T., Venkatapathy, R., & Harten, P. (2008) · QSAR & Combinatorial Science · doi:10.1002/qsar.200810084 · Cited by 196
Curation of chemogenomics data
Fourches, D., Muratov, E., & Tropsha, A. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1881 · Cited by 192
Self-citationRodriguez, A. L., Grier, M. D., Jones, C. K., Herman, E. J., Kane, A. S., Smith, R. L., Williams, R., Zhou, Y., Marlo, J. E., Days, E. L., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067207 · Cited by 178
The holistic integration of virtual screening in drug discovery
Tanrikulu, Y., Krüger, B., & Proschak, E. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.007 · Cited by 176
Existing and Developing Approaches for QSAR Analysis of Mixtures
Muratov, E. N., Varlamova, E. V., Artemenko, A. G., Полищук, П. Г., & Kuz’min, V. Е. (2012) · Molecular Informatics · doi:10.1002/minf.201100129 · Cited by 139
Self-citationGomes, M. D. N., Braga, R. C., Grzelak, E. M., Neves, B. J., Muratov, E. N., Ma, R., Klein, L. L., Cho, S., de Oliveira, G. R., Franzblau, S. G., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.026 · Cited by 133
Self-citationHow far can virtual screening take us in drug discovery?
Kar, S., & Roy, K. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.761204 · Cited by 128
A quality alert and call for improved curation of public chemistry databases
Williams, A. J., & Ekins, S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.07.007 · Cited by 114
Ban, F., Dalal, K., Li, H., LeBlanc, E., Rennie, P. S., & Cherkasov, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00137 · Cited by 109
Discovery of Novel Antimalarial Compounds Enabled by QSAR-Based Virtual Screening
Zhang, L., Fourches, D., Sedykh, A., Zhu, H., Golbraikh, A., Ekins, S., Clark, J. A., Connelly, M., Sigal, M. S., Hodges, D., et al. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300421n · Cited by 101
Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery
Ekins, S., Lage de Siqueira-Neto, J., McCall, L.-I., Sarker, M., Yadav, M., Ponder, E. L., Kallel, E. A., Kellar, D., Chen, S., Arkin, M., et al. (2015) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0003878 · Cited by 93
Neves, B. J., Dantas, R. F., Senger, M. R., Melo-Filho, C. C., Valente, W. C. G., de Almeida, A. C. M., Rezende-Neto, J. M., Lima, E. F. C., Paveley, R. A., Furnham, N., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02038 · Cited by 91
Self-citationInfluenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity
Laborda, P., Wang, S., & Voglmeir, J. (2016) · Molecules · doi:10.3390/molecules21111513 · Cited by 85
Benchmarking Ligand-Based Virtual High-Throughput Screening with the PubChem Database
Butkiewicz, M., Lowe, E. W., Mueller, R., Mendenhall, J., Teixeira, P. L., Weaver, C. D., & Meiler, J. (2013) · Molecules · doi:10.3390/molecules18010735 · Cited by 81
Maximizing computational tools for successful drug discovery
Nantasenamat, C., & Prachayasittikul, V. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1016497 · Cited by 69
Southan, C., Várkonyi, P., & Mureşan, S. (2009) · Journal of Cheminformatics · doi:10.1186/1758-2946-1-10 · Cited by 67
QSAR-Driven Discovery of Novel Chemical Scaffolds Active against Schistosoma mansoni
Melo-Filho, C. C., Dantas, R. F., Braga, R. C., Neves, B. J., Senger, M. R., Valente, W. C. G., Rezende-Neto, J. M., Chaves, W. T., Muratov, E. N., Paveley, R. A., et al. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00055 · Cited by 56
Self-citationNew drugs for the treatment of Mycobacterium tuberculosis infection
AlMatar, M., AlMandeal, H., Var, İ., Kayar, B., & Köksal, F. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.105 · Cited by 49
Mueller, R., Rodriguez, A. L., Dawson, E. S., Butkiewicz, M., Nguyen, T., Oleszkiewicz, S., Bleckmann, A., Weaver, C. D., Lindsley, C. W., Conn, P. J., et al. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn9000389 · Cited by 47
Mueller, R., Dawson, E. S., Meiler, J., Rodriguez, A. L., Chauder, B. A., Bates, B. S., Felts, A. S., Lamb, J. P., Menon, U. N., Jadhav, S. B., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201100510 · Cited by 45
The therapeutic potential of 5-HT1A receptors: a patent review
Lacivita, E., Pilato, P. D., Giorgio, P. D., Colabufo, N. A., Berardi, F., Perrone, R., & Leopoldo, M. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.703654 · Cited by 45
Luo, M., Wang, X. S., Roth, B. L., Golbraikh, A., & Tropsha, A. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400460q · Cited by 37
Ligand-Based Virtual Screening in a Search for Novel Anti-HIV-1 Chemotypes
Kurczyk, A., Warszycki, D., Musioł, R., Kafel, R., Bojarski, A. J., & Polański, J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00295 · Cited by 30
An Overview of Currently Available Antimalarials
Gorobets, N. Y., Sedash, Y. V., Singh, B. K., Poonam, P., & Rathi, B. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170130123520 · Cited by 23
How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
Garbelli, A., Riva, V., Crespan, E., & Maga, G. (2017) · Biochemical Journal · doi:10.1042/bcj20160772 · Cited by 22
Computational chemistry in pharmaceutical research: at the crossroads
Bajorath, J. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9488-z · Cited by 7
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
Gan, B. H., Gaynord, J., Rowe, S. M., Deingruber, T., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00729c · Cited by 511
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
Uncertainty quantification: Can we trust artificial intelligence in drug discovery?
Yu, J., Wang, D., & Zheng, M. (2022) · iScience · doi:10.1016/j.isci.2022.104814 · Cited by 59
Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma
Raymond, J. H., Aktary, Z., Larue, L., & Delmas, V. (2022) · Cancers · doi:10.3390/cancers14030706 · Cited by 20
Metadata
- Authors
- Neves, B. J., Braga, R. C., Melo-Filho, C. C., Moreira-Filho, J. T., Muratov, E. N., & Andrade, C. H.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-13
- Volume
- 9
- Pages
- 1275-1275
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2901719664
- Cited by
- 494
- References
- 43
- FWCI
- 22.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.